Business
    Next Score View the next score

    Map Pharmaceuticals

    Regulators did not reject Map’s inhalable migraine drug because of safety or effectiveness and don’t want new studies, CEO Tim Nelson said - it was about manufacturing issues. Levadex is an inhaled form of a 60-year-old migraine drug that’s injected. Map, of Mountain View, Calif., seeks approval for its use in patients with 15 or fewer migraines a month; it would be Map’s first marketed product. The shares’ drop was a “knee-jerk reaction,’’ said Liana Moussatos, at Wedbush Securities. “It sounds like there are just manufacturing issues, no clinical safety issues.’’

    Advertisement